MedTrace Logo

A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma

NCT04455139 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2023-10-03

No results posted yet for this study

Summary

While 95% of patients with retinoblastoma can be cured nowadays, treatment of relapse remains challenging, ending often in enucleation and/or radiotherapy. In the last 10 years, new treatment modalities have been developed to give the chance of cure also in relapse, avoiding enucleation which results in esthetic sequelae and orbital growth problems, and radiotherapy which significantly increases the risk of secondary cancers in hereditary retinoblastoma. The current protocol aims at covering all types of relapses in retinoblastoma, with treatments adapted to the site of relapse, at harmonizing the new eye- and vision-preserving treatment procedures, and evaluating their efficacy and toxicity.

Conditions

  • Eye Cancer, Retinoblastoma

Interventions

DRUG

Topotecan

intravitreal or intra-arterial administration of topotecan

DRUG

Melphalan

intravitreal or intra-arterial administration of topotecan

Sponsors & Collaborators

  • Prof. Beck Popovic Maja

    lead OTHER

Principal Investigators

  • Maja Beck Popovic, Prof · University of Lausanne Hospitals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Months
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-15
Primary Completion
2023-05-22
Completion
2023-05-22

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04455139 on ClinicalTrials.gov